1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.’s Acquisition of Alesta Therapeutics
ALE1 advanced by 1cBio prior to its worldwide licensing agreement [...]
1cBio and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio’s PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia Gallery1cBio and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio’s PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia
1cBio and Lee’s Pharmaceutical Holdings Limited Enter into Exclusive Licensing Agreement to Develop and Commercialize 1cBio’s PARP1 Inhibitor OC-3 for Oncology in Greater China and Southeast Asia
OC-3 is a potentially best-in-class PARP1 inhibitor for cancers that [...]
1cBio and Alesta Therapeutics Announce Exclusive Global Licensing Agreement for a Novel Potentially First-in-Class Small Molecule for Hypophosphatasia Gallery1cBio and Alesta Therapeutics Announce Exclusive Global Licensing Agreement for a Novel Potentially First-in-Class Small Molecule for Hypophosphatasia
1cBio and Alesta Therapeutics Announce Exclusive Global Licensing Agreement for a Novel Potentially First-in-Class Small Molecule for Hypophosphatasia
SAN FRANCISCO and LEIDEN, Netherlands, Jan. 8, 2025 /PRNewswire/ -- 1cBio, [...]
